Ray Therapeutics secures $125 Million Series B financing led by Janus Henderson Investors to advance vision restoration treatments.
Amount Raised
$125 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareScience And EngineeringInvestors
Description
Ray Therapeutics announced the closing of an upsized $125 million Series B financing round. This funding will support late-stage clinical development for RTx-015 and clinical studies for RTx-021. The round was led by Janus Henderson Investors with participation from several other firms. The financing reflects strong support from both new and existing investors.
Quick answer
Ray Therapeutics raised $125 Million in a Series B round, dated April 21, 2026. Investors: Norwest Venture Partners, Deerfield Management, Janus Henderson Investors, MRL Ventures Fund, 4BIO Capital, Novo Holdings A/S, Platanus and Adage Capital Management. Ray Therapeutics is based in San Diego, California, United States.
- How much did Ray Therapeutics raise?
- Ray Therapeutics raised $125 Million in a Series B round on April 21, 2026.
- Who invested in Ray Therapeutics?
- Norwest Venture Partners, Deerfield Management, Janus Henderson Investors, MRL Ventures Fund, 4BIO Capital, Novo Holdings A/S, Platanus and Adage Capital Management are named as investors in this round.
- What does Ray Therapeutics do?
- Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and..
- Where is Ray Therapeutics based and how big is it?
- Ray Therapeutics is based in San Diego, California, United States. Fundz records about 33 employees.
- Who are the decision-makers at Ray Therapeutics?
- Fundz holds 1 contact at Ray Therapeutics, including the Sr Director, CMC Analytical. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Ray Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- OliX Pharmaceuticals raised $89M (Post-IPO Equity) on June 4, 2026.
- Advanced NanoTherapies raised $31M (Series B) on June 2, 2026.
- Psilera raised $8.8M (Seed) on May 28, 2026.
- Degron Therapeutics raised $40M (Series A) on May 14, 2026.
- Maze Therapeutics raised $145M (Post-IPO Equity) on April 22, 2026.
- Orthogon Therapeutics raised $11M (Funding Round) on April 17, 2026.
Who to call at Ray Therapeutics, and when
A new round usually means Ray Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ray Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ray Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ray Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ray Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRay Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.